Cartilage-derived retinoic acid-senstive protein

Drug Profile

Cartilage-derived retinoic acid-senstive protein

Alternative Names: Melanoma inhibitory activity; MIA

Latest Information Update: 04 Feb 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Scil Technology
  • Class
  • Mechanism of Action Cartilage replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cartilage disorders

Most Recent Events

  • 16 Jan 2008 Cartilage-derived retinoic acid-sensitive protein (CD-RAP) licensed to Pfizer Inc. worldwide
  • 23 Feb 2004 CD-RAP is available for licensing (http://www.scilbiomedicals.com)
  • 31 Aug 2003 Preclinical trials in Cartilage disorders in Europe (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top